IL-1β Signaling Drives Aggressive TCF3::HLF B-ALL and Bone Lesions

B-cell acute lymphoblastic leukemia (B-ALL) presents a wide spectrum of clinical outcomes, largely dictated by underlying genetic subtypes. While combination chemotherapy has improved survival, certain aggressive forms remain highly challenging, often developing resistance to standard agents like glucocorticoids [1]. The interplay between oncogenic drivers and the tumor microenvironment is increasingly recognized as a key factor in leukemogenesis. For example, aberrant inflammatory signaling, such as elevated interleukin-6 (IL-6), can promote tumor growth and create therapeutic vulnerabilities in specific contexts like PAX5-mutant B-ALL [2]. The ongoing search for deregulated transcription factors and their coregulatory networks continues to be a priority for overcoming treatment failure [3]. A recent study now provides a mechanistic link between a specific fusion protein and an inflammatory cascade in a particularly lethal B-ALL subtype.